Not exact matches
To further analyze
whether FGFR fusions are present across
different types of
cancers, the researchers extended their assessment and analyzed data generated from an internal cohort of 322 patients, as well as from a large cohort of 2,053 patients recruited to The
Cancer Genome Atlas.
Answering important clinical questions — such as
whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with
different types of
cancer.
Blueprint will see where it stands after adding more patients with
different cancer types to the Phase 1 study and focusing more on how long their responses last, rather than just
whether they respond at all.
Beyond the expansion of the collection of barcoded cell lines for testing larger panels of compounds, next steps will include determining
whether PRISM can be used to study the complex interactions between
different cell
types found within tumors, or to study tumor evolution during
cancer development or after
cancer treatment.